Beigene (NASDAQ:ONC) Given New $317.00 Price Target at JPMorgan Chase & Co.

Beigene (NASDAQ:ONC - Get Free Report) had its target price hoisted by research analysts at JPMorgan Chase & Co. from $311.00 to $317.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 29.44% from the company's current price.

A number of other brokerages have also recently weighed in on ONC. Bank of America raised shares of Beigene from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $207.00 to $320.00 in a research report on Monday, March 3rd. Royal Bank of Canada started coverage on Beigene in a report on Monday, April 7th. They set an "outperform" rating and a $312.00 target price on the stock. JMP Securities set a $348.00 price target on Beigene in a report on Friday, February 28th. Macquarie lifted their price objective on Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Finally, Guggenheim reiterated a "buy" rating on shares of Beigene in a research report on Wednesday, April 16th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $318.88.

Beigene Stock Down 4.4 %

NASDAQ ONC traded down $11.26 on Monday, reaching $244.90. The company had a trading volume of 488,142 shares, compared to its average volume of 491,171. Beigene has a 52 week low of $141.31 and a 52 week high of $287.88. The company has a 50 day moving average of $247.84. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The company has a market capitalization of $24.21 billion, a PE ratio of -29.72, a price-to-earnings-growth ratio of 7.73 and a beta of 0.49.

Beigene (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.09 billion. As a group, analysts forecast that Beigene will post -5.82 EPS for the current year.

Insider Buying and Selling

In other Beigene news, SVP Chan Henry Lee sold 1,202 shares of Beigene stock in a transaction on Friday, February 21st. The shares were sold at an average price of $258.04, for a total value of $310,164.08. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Xiaodong Wang sold 8,146 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $254.58, for a total transaction of $2,073,808.68. Following the sale, the insider now directly owns 5,240,882 shares in the company, valued at $1,334,223,739.56. This trade represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,146,048 shares of company stock worth $295,198,300. 6.62% of the stock is owned by corporate insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.